Brief: Ironwood Pharmaceuticals Announces FDA Approval Of New Indication For LINZESS
12/06/2023 21:19
June 12 (Reuters) - Ironwood Pharmaceuticals Inc
IRWD.O :
* IRONWOOD PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF NEW
INDICATION FOR LINZESS® (LINACLOTIDE) FOR THE TREATMENT OF
FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS AGES 6-17
YEARS-OLD
* IRONWOOD PHARMA - LINZESS 72MCG AVAILABLE TO TREAT
FUNCTIONAL
CONSTIPATION FOR AGES 6-17 YEARS, WITH IMMEDIATE ACCESSIBILITY
FOR MOST PATIENTS
Source text for Eikon: ID:nBw76PQSKa
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation